These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. Walser M N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778 [No Abstract] [Full Text] [Related]
8. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P; N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519 [TBL] [Abstract][Full Text] [Related]
10. [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?]. Arner P Lakartidningen; 2002 Jan; 99(1-2):80-2. PubMed ID: 11871182 [No Abstract] [Full Text] [Related]
11. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. Palmer AJ; Valentine WJ; Ray JA Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649 [TBL] [Abstract][Full Text] [Related]
12. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S; N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518 [TBL] [Abstract][Full Text] [Related]
13. [Evidence based treatment of diabetic nephropathy]. Sugimoto T Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244 [No Abstract] [Full Text] [Related]
14. Angiotensin II receptor blockade in diabetic nephropathy. Lewis EJ Am J Hypertens; 2003 Jan; 16(1):100-1. PubMed ID: 12517696 [No Abstract] [Full Text] [Related]
15. [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. Schnack C; Schernthaner G Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165 [TBL] [Abstract][Full Text] [Related]
16. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage]. MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422 [No Abstract] [Full Text] [Related]
17. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys]. MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191 [No Abstract] [Full Text] [Related]
18. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients. Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619 [No Abstract] [Full Text] [Related]
19. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL. Coats AJ Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726 [No Abstract] [Full Text] [Related]
20. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I; N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]